{"id":37634,"date":"2016-10-12T06:39:42","date_gmt":"2016-10-12T10:39:42","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37634"},"modified":"2016-10-12T06:39:42","modified_gmt":"2016-10-12T10:39:42","slug":"celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634","title":{"rendered":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Celldex Therapeutics, Inc. (NASDAQ:CLDX)<\/strong> has presented results from the phase-2 study of glembatumumab vedotin for the treatment of stage 3-4 of metastatic melanoma. The drug is a monoclonal antibody-drug conjugate, which targets an over-expressed marker, glycoprotein NMB, in melanoma patients. The company presented the results at the ESMO 2016 Congress, on October 9, held in Copenhagen, Denmark. A total of 62 patients had been enrolled in the study, out of which 7 demonstrated confirmed response. Moreover, another 3 patients demonstrated single time-point responses.<\/p>\n<p style=\"text-align: justify;\">The CMO Celldex, Thomas Davis, stated that it was evident from the results that metastatic melanoma is a targeted indication for the drug. He further stated that they were encouraged by the results seen to date and they intend to leverage the immune system, with the help of combination therapy, as the next step for the indication. The company noted that 53% of the patients demonstrated stable disease within the first 6-weeks. Moreover, 52% of the enrolled patients observed tumor shrinkage as well.<\/p>\n<p style=\"text-align: justify;\">The news had helped Celldex remain stable, in the stock market, but it was short lived, as the stock once again plunged, during yesterday\u2019s session. Earlier, Mr. Davis had participated in a fireside chat, at the Leerink Partners Rare Disease &amp; Immuno-Oncology Roundtable, on September 29, 2016. He was also accompanied by CLDX CEO, Anthony Marucci. Following the presentation, the stock slowly gained ground, before spiking on October 3, adding almost $0.5 to its share value.<\/p>\n<p style=\"text-align: justify;\">One of the red flags around CLDX is the fact that it is irregular with its business updates. Prior to attending the conference, the company had issued its last press-release on August 11, announcing the appointment of Elizabeth Crowley, as the new Chief Product Development Officer. Mrs. Crowley has been a Senior VP at the company for quite some time now and had previously been associated with product development as well. Her area of expertise mostly includes drug development programs, which is invaluable for the company at this stage.<\/p>\n<p style=\"text-align: justify;\">Celldex Therapeutics, Inc. (NASDAQ:CLDX) lost 8.96% of its share value, during the October 11 trading session, to close at $3.86 per share.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celldex Therapeutics, Inc. (NASDAQ:CLDX) has presented results from the phase-2 study of glembatumumab vedotin for the treatment of stage 3-4 of metastatic melanoma. The drug [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":37635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12146,12144,12143,12145],"stock_ticker":[],"class_list":["post-37634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-anthony-marucci","tag-celldex-therapeutics-inc","tag-celldex-therapeutics-inc-nasdaqcldx","tag-nasdaqcldx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Celldex Therapeutics, Inc. (NASDAQ:CLDX) has presented results from the phase-2 study of glembatumumab vedotin for the treatment of stage 3-4 of metastatic melanoma. The drug [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-12T10:39:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"840\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study\",\"datePublished\":\"2016-10-12T10:39:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg\",\"keywords\":[\"Anthony Marucci\",\"Celldex Therapeutics Inc.\",\"Celldex Therapeutics Inc. (NASDAQ:CLDX)\",\"NASDAQ:CLDX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\",\"name\":\"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg\",\"datePublished\":\"2016-10-12T10:39:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg\",\"width\":840,\"height\":420},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634","og_locale":"en_US","og_type":"article","og_title":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR","og_description":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) has presented results from the phase-2 study of glembatumumab vedotin for the treatment of stage 3-4 of metastatic melanoma. The drug [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2016-10-12T10:39:42+00:00","og_image":[{"width":840,"height":420,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study","datePublished":"2016-10-12T10:39:42+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg","keywords":["Anthony Marucci","Celldex Therapeutics Inc.","Celldex Therapeutics Inc. (NASDAQ:CLDX)","NASDAQ:CLDX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634","url":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634","name":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg","datePublished":"2016-10-12T10:39:42+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/10\/celldex-logo.jpg","width":840,"height":420},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celldex-therapeutics-inc-nasdaqcldx-presents-results-from-metastatic-melanoma-study-37634#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) Presents Results From Metastatic Melanoma Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37634"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37634\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37635"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37634"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}